Enhancing Patient Care: Transitioning from Ecul...

Evenamide (NW-3509)– derived from Newron's ion channel program, tackles schizophrenia with its unique mechanism, balancing glutamate levels and blocking aberrant sodium channel activity to restore neuronal function without compromising normal excitability. Evenamide, based on a new concept in treating inadequat...

Ulotaront (SEP-363856), a novel investigational drug, by Sumitomo Pharma/Otsuka Pharmaceuticals, has shown promise as a potential alternative treatment method for schizophrenia, as it lessens the negative metabolic side effects TAAR1 has emerged as a promising target in the treatment of schizophrenia and other ...

Unlike traditional antipsychotic medications that block dopamine receptors, CVL-231 selectively modulates the M4 receptor in the brain and provides antipsychotic effects without the need for titration. CVL-231, a once-daily medication, with enhanced potential for treatment adherence, seeks to bypass gastrointes...

KarXT, likely to receive the nod from the US FDA by late 2024, will significantly impact the market with the potential to reduce the positive, negative, and cognitive symptoms of schizophrenia. The long-term data is encouraging, signaling that KarXT is not associated with “burdensome side effects” the major imp...

In the landscape of schizophrenia treatment, there are significant gaps that affect patients' lives profoundly. From the foggy terrain of early detection, where symptoms blur the lines between schizophrenia and other mental health conditions, to the daunting landscape of treatment resistance and relapse, where stan...

LYN-005’s once-weekly dosing regimen reduces the pill burden for individuals with schizophrenia and schizoaffective disorders compared to traditional daily medications such as Risperdal. A unique capsule design consisting of six polymeric arms connected to a flexible core, encapsulated in a folded star-shaped f...